🇺🇸 FDA
Patent

US 12018087

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject

granted A61KA61K47/6807A61K47/6849

Quick answer

US patent 12018087 (Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject) held by Dyne Therapeutics, Inc. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K47/6807, A61K47/6849, A61K47/6889, A61P